• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人类接种一剂 Ad26.COV2.S 疫苗后对 SARS-CoV-2 的抗体进化。

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.

机构信息

Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.

Laboratory of Retrovirology, The Rockefeller University, New York, NY.

出版信息

J Exp Med. 2022 Aug 1;219(8). doi: 10.1084/jem.20220732. Epub 2022 Jul 1.

DOI:10.1084/jem.20220732
PMID:35776090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9253517/
Abstract

The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBD-specific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.

摘要

单次剂量的 Ad.26.COV.2（强生）疫苗引发的中和抗体水平较低，在预防感染方面的效果也不如两种现有 mRNA 疫苗中的任何一种。此外，在奥密克戎疫情期间，Ad.26.COV.2 在预防重症疾病方面的效果也较差。在这里，我们研究了单次剂量 Ad.26.COV.2 疫苗接种后的记忆 B 细胞反应。与 mRNA 疫苗相比，Ad.26.COV.2 接种者在接种后 1.5 或 6 个月时，RBD 特异性记忆 B 细胞的数量明显较低。尽管数量较少，但记忆 B 细胞反应的总体质量似乎相似，因此两种疫苗类型引发的记忆抗体对 SARS-CoV-2 武汉株、Delta 和奥密克戎 BA.1 变异株均显示出相当的中和效力。这些数据有助于解释为什么用 mRNA 疫苗对 Ad.26.COV.2 疫苗接种者进行加强免疫是有效的，以及为什么 Ad26.COV2.S 疫苗在奥密克戎疫情期间仍能保持对重症疾病的部分保护效力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/b9567d8d7a39/JEM_20220732_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/6b29af5538fe/JEM_20220732_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/f243383b449c/JEM_20220732_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/10f19c0db455/JEM_20220732_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/8a7aa9cd30b1/JEM_20220732_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/026db5ecb715/JEM_20220732_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/7126c3956a6b/JEM_20220732_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/fc3155320fd4/JEM_20220732_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/21777676890d/JEM_20220732_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/b9567d8d7a39/JEM_20220732_FigS4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/6b29af5538fe/JEM_20220732_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/f243383b449c/JEM_20220732_FigS1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/10f19c0db455/JEM_20220732_Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/8a7aa9cd30b1/JEM_20220732_FigS2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/026db5ecb715/JEM_20220732_FigS3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/7126c3956a6b/JEM_20220732_Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/fc3155320fd4/JEM_20220732_Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/21777676890d/JEM_20220732_Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f7d4/9253517/b9567d8d7a39/JEM_20220732_FigS4.jpg

相似文献

1
Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.人类接种一剂 Ad26.COV2.S 疫苗后对 SARS-CoV-2 的抗体进化。
J Exp Med. 2022 Aug 1;219(8). doi: 10.1084/jem.20220732. Epub 2022 Jul 1.
2
Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.mRNA-1273、BNT162b2 和 Ad26.COV2.S 疫苗接种者对包括德尔塔和奥密克戎在内的关注变异株 SARS-CoV-2 的中和抗体。
J Med Virol. 2022 Dec;94(12):5678-5690. doi: 10.1002/jmv.28032. Epub 2022 Aug 6.
3
Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.疫苗对 SARS-CoV-2 奥密克戎变异株增强的中和抗体迅速下降。
Cell Rep Med. 2022 Jul 19;3(7):100679. doi: 10.1016/j.xcrm.2022.100679. Epub 2022 Jun 20.
4
Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques.加强针接种 Ad26.COV2.S 或奥密克戎变异株适应疫苗可增强恒河猴对 SARS-CoV-2 奥密克戎的免疫原性和效力。
Nat Commun. 2023 Apr 7;14(1):1944. doi: 10.1038/s41467-023-37715-2.
5
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.Ad26.COV2.S 的免疫原性和疗效：一种基于腺病毒载体的 COVID-19 疫苗。
Immunol Rev. 2022 Sep;310(1):47-60. doi: 10.1111/imr.13088. Epub 2022 Jun 11.
6
Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.同源和异源加强免疫在 Ad26.COV2.S 初免个体中的体液和细胞免疫原性：突破性感染的比较。
Front Immunol. 2023 Mar 7;14:1131229. doi: 10.3389/fimmu.2023.1131229. eCollection 2023.
7
Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.检测对 Ad26.COV2.S 疫苗无应答的 HIV-1 感染个体中预先存在的针对 Ad26 的中和抗体。
Infection. 2023 Dec;51(6):1657-1667. doi: 10.1007/s15010-023-02035-6. Epub 2023 Apr 17.
8
Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.针对 SARS-CoV-2 武汉-Hu-1 株及其关注变异株的中和活性的比较分析：基于假病毒的中和测定的性能评估。
Front Immunol. 2022 Sep 26;13:981693. doi: 10.3389/fimmu.2022.981693. eCollection 2022.
9
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.在未免疫的仓鼠中使用Ad26.COV2.S或奥密克戎适应疫苗进行加强免疫可预防奥密克戎BA.2。
NPJ Vaccines. 2023 Mar 16;8(1):40. doi: 10.1038/s41541-023-00633-x.
10
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.1 剂 Ad26.COV2.S 诱导的持久抗体反应，并在加强后显著增加：2 项随机临床试验。
Vaccine. 2022 Jul 30;40(32):4403-4411. doi: 10.1016/j.vaccine.2022.05.047. Epub 2022 Jun 3.

引用本文的文献

1
Revealing the significance of IL-2 and IL-5 in SARS-CoV-2-specific T-cell responses in kidney transplant recipients.揭示白细胞介素-2和白细胞介素-5在肾移植受者中针对严重急性呼吸综合征冠状病毒2特异性T细胞反应中的意义。
Npj Viruses. 2024 Feb 14;2(1):7. doi: 10.1038/s44298-024-00015-7.
2
The Parameters of Long-Term Humoral Immunity Induced by a Single Injection of the Sputnik Light Vaccine Among Noninfected Volunteers and Those Infected with SARS-CoV-2.单次注射“卫星V”轻型疫苗在未感染志愿者和感染新冠病毒者中诱导产生的长期体液免疫参数
Acta Naturae. 2025 Jan-Mar;17(1):52-63. doi: 10.32607/actanaturae.27529.
3
Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.

本文引用的文献

1
Durability of Protection Post-Primary COVID-19 Vaccination in the United States.美国新冠病毒疫苗初免后的保护持久性
Vaccines (Basel). 2022 Sep 3;10(9):1458. doi: 10.3390/vaccines10091458.
2
Humoral and cellular immune memory to four COVID-19 vaccines.体液免疫和细胞免疫对四种 COVID-19 疫苗的记忆。
Cell. 2022 Jul 7;185(14):2434-2451.e17. doi: 10.1016/j.cell.2022.05.022. Epub 2022 May 27.
3
Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.同源和异源新冠病毒加强针针对奥密克戎毒株的有效性
针对mRNA-1273和NVX-CoV2373新冠疫苗的多克隆抗体反应的结构血清学
bioRxiv. 2024 Dec 12:2024.12.11.628030. doi: 10.1101/2024.12.11.628030.
4
Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding.同源而非异源的新冠病毒疫苗加强针可引发IgG4+ B细胞并增强对奥密克戎变异株的结合。
NPJ Vaccines. 2024 Jul 17;9(1):129. doi: 10.1038/s41541-024-00919-8.
5
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.杨森公司的 Ad26.COV2.S 单次剂量 COVID-19 疫苗在乌干达的 12 个月队列研究中引起了强烈和持久的抗刺突 IgG 抗体反应。
Front Immunol. 2024 May 8;15:1384668. doi: 10.3389/fimmu.2024.1384668. eCollection 2024.
6
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S.接种Ad26.COV2.S疫苗后B细胞体细胞超突变。
iScience. 2024 Apr 9;27(5):109716. doi: 10.1016/j.isci.2024.109716. eCollection 2024 May 17.
7
Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain.异源 SARS-CoV-2 刺突蛋白加强剂可引发针对受体结合域的持久和广泛的抗体反应。
Nat Commun. 2023 Mar 15;14(1):1451. doi: 10.1038/s41467-023-37128-1.
8
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.两剂 ChAdOx1 nCov-19（AZD1222）后免疫应答的持久性：两项随机对照试验的 1 年随访结果。
Clin Exp Immunol. 2023 Mar 24;211(3):280-287. doi: 10.1093/cei/uxad013.
9
Humoral immunity for durable control of SARS-CoV-2 and its variants.用于持久控制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）及其变体的体液免疫。
Inflamm Regen. 2023 Jan 12;43(1):4. doi: 10.1186/s41232-023-00255-9.
10
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens.组合 COVID-19 疫苗接种方案诱导的针对 SARS-CoV-2 的体液免疫。
J Exp Med. 2022 Oct 3;219(10). doi: 10.1084/jem.20220826. Epub 2022 Aug 25.
N Engl J Med. 2022 Jun 23;386(25):2433-2435. doi: 10.1056/NEJMc2203165. Epub 2022 May 25.
4
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine.第三次接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）mRNA疫苗后对奥密克戎反应性B细胞记忆的有效回忆
Cell. 2022 May 26;185(11):1875-1887.e8. doi: 10.1016/j.cell.2022.04.009. Epub 2022 Apr 8.
5
Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.Ad26.COV2.S和BNT162b2疫苗在南非针对奥密克戎变种的有效性
N Engl J Med. 2022 Jun 9;386(23):2243-2245. doi: 10.1056/NEJMc2202061. Epub 2022 May 4.
6
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.分析记忆 B 细胞鉴定出变异 SARS-CoV-2 刺突蛋白 N 端结构域上的保守中和表位。
Immunity. 2022 Jun 14;55(6):998-1012.e8. doi: 10.1016/j.immuni.2022.04.003. Epub 2022 Apr 7.
7
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost.接种 SARS-CoV-2 mRNA 加强针后，记忆 B 细胞的效力和广度增加。
Nature. 2022 Jul;607(7917):128-134. doi: 10.1038/s41586-022-04778-y. Epub 2022 Apr 21.
8
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.同源和异源 COVID-19 加强针在接种 1 剂 Ad.26.COV2.S（强生[詹森]）疫苗后的有效性：成人因 COVID-19 前往急诊和紧急护理就诊和住院的情况 - VISION 网络，10 个州，2021 年 12 月至 2022 年 3 月。
MMWR Morb Mortal Wkly Rep. 2022 Apr 1;71(13):495-502. doi: 10.15585/mmwr.mm7113e2.
9
Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.南非卫生保健工作者中 Ad26.COV2.S 疫苗的有效性（Sisonke 研究）：一项单臂、开放标签、3B 期、实施研究的结果。
Lancet. 2022 Mar 19;399(10330):1141-1153. doi: 10.1016/S0140-6736(22)00007-1.
10
Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations.Ad26.COV2.S 疫苗与 BNT162b2 疫苗对 COVID-19 住院治疗的有效性。
JAMA Netw Open. 2022 Mar 1;5(3):e220868. doi: 10.1001/jamanetworkopen.2022.0868.